Vascular endothelial growth factor as a biomarker for the early detection of cancer using a whole cell-based biosensor

Vascular endothelial growth factor (VEGF) is a cytokine and endothelial cell (EC) mitogen that has been studied for its role in angiogenesis of malignant tumors. Elevated quantities of VEGF in the serum and plasma of patients have been correlated with the presence of cancer and metastasis. Since VEGF induces hyperpermeability of EC monolayers, this protein can be detected in vitro with a whole cell-based biosensor. This biosensor consists of a confluent monolayer of human umbilical vein endothelial cells (HUVECs) attached to a cellulose triacetate (CTA) membrane of an ion-selective electrode (ISE). Previous studies regarding this biosensor have shown that when the biosensor was exposed to a model toxin, such as histamine, the response of the biosensor served as an indirect measurement of the presence of histamine. Similarly, the biosensor responds to the presence of VEGF, but is much more sensitive because VEGF is known to be 50,000-fold more potent than histamine when inducing EC hyperpermeability. The ISE response increased with increasing VEGF concentration. Since lower concentrations required more exposure time, the detection limit was established as a function of exposure time (2–10 h). The practical applicability of the biosensor was also established with cultured human melanoma cells WM793 (nonmetastatic) and 1205LU (metastatic). The resultant change in the potential values revealed significant production of VEGF from the 1205LU cells. A VEGF ELISA was performed to confirm the VEGF concentration in each sample. The biosensor closely predicted the concentrations determined through the ELISA. These results support the use of a cell-based ISE as a quick screening method for the presence of VEGF.

[1]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. , 1999, Current topics in microbiology and immunology.

[2]  L. Rubbia‐Brandt,et al.  Elevated levels of angiogenic cytokines in the plasma of cancer patients , 2000, International journal of cancer.

[3]  Anthony J. Guidi,et al.  Vascular permeability factor (Vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast , 1997, Cancer.

[4]  C. Bucana,et al.  Regulation of distinct steps of angiogenesis by different angiogenic molecules. , 1998, International journal of oncology.

[5]  P. Kantoff,et al.  Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. , 1999, Urology.

[6]  Harold E. Dvorak,et al.  Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin , 1996, The Journal of experimental medicine.

[7]  H. Sakahara,et al.  Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. , 1997, British Journal of Cancer.

[8]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[9]  Anthony J. Guidi,et al.  Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[11]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Harold E. Dvorak,et al.  Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors , 1997, Thrombosis and Haemostasis.

[13]  H. Joensuu,et al.  High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer , 1998, International journal of cancer.

[14]  A. Bergh,et al.  Castration‐induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer , 2001, BJU international.

[15]  G. Cha,et al.  Asymmetric membrane-based potentiometric solid-state ion sensors , 1996 .

[16]  Jae Ho Shin,et al.  Asymmetric cellulose acetate membrane-based carbonate- and chloride-selective electrodes , 1995 .

[17]  G. Cha,et al.  Potentiometric ion- and bio-selective electrodes based on asymmetric cellulose acetate membranes. , 1989, Talanta.

[18]  S. Oh,et al.  Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. , 2004, Japanese journal of clinical oncology.

[19]  L. Bachas,et al.  Effect of surface-attached heparin on the response of potassium-selective electrodes. , 1996, Analytical chemistry.

[20]  G. Palade,et al.  Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. , 1995, Journal of cell science.

[21]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[22]  A. Dvorak,et al.  The Vesiculo–Vacuolar Organelle (VVO): A New Endothelial Cell Permeability Organelle , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[23]  R. Kumar,et al.  Angiogenic molecules and cancer metastasis. , 1998, In vivo.

[24]  R. Koncki,et al.  Biochemical modifications of membrane ion-selective sensors , 1997 .

[25]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[26]  M. Korc,et al.  Pancreatic cancer cell‐derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo , 2001, International journal of cancer.

[27]  A. Bergh,et al.  Vascular endothelial growth factor content in metastasizing and nonmetastasizing dunning prostatic adenocarcinoma , 2000, The Prostate.

[28]  M. Corada,et al.  Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. , 1998, Journal of cell science.

[29]  R. Stouffer,et al.  Vascular endothelial growth factor production by human luteinized granulosa cells in vitro. , 1997, Human reproduction.

[30]  D. Shasby,et al.  Histamine stimulates phosphorylation of adherens junction proteins and alters their link to vimentin. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[31]  R K Jain,et al.  Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. , 1999, Cancer research.

[32]  H. Dvorak,et al.  Vascular permeability factor, tumor angiogenesis and stroma generation. , 1994, Invasion & metastasis.

[33]  L. Bachas,et al.  Development of a Whole-Cell-Based Biosensor for Detecting Histamine as a Model Toxin , 2004 .

[34]  M. Lampugnani,et al.  Histamine induces tyrosine phosphorylation of endothelial cell-to-cell adherens junctions. , 1999, Arteriosclerosis, thrombosis, and vascular biology.